CYTK: Insiders Sell Into a Sharp Rally Ahead of Q1 Print
Cytokinetics heads into its Q1 2026 earnings report today with an unusual split: a 27% surge in the past week, and a parade of insider sellers cashing out at every step. The stock's move is striking. Shares closed at…